Leadbio Secures Tens of Millions in Pre-A Funding to Advance Bioengineered Vascular Grafts

VCBeat has learned that LEADBIO (Hangzhou) Co., Ltd. (hereinafter referred to as“LEADBIO,” after securing a tens-of-millions-yuan angel round led by Taiyu Investment, has once again raised tens of millions of yuan in Pre-A financing from Boxing Capital within just a few months. LEADBIO stated, “The proceeds from this financing round will be used for the preclinical research on the company’s bioengineered artificial blood vessels and the development of new products.”

According to reports, LEADBIO was founded in 2019 and is located in the Medicine Port of Hangzhou Qiantang New Area. The company is dedicated to the research and development of tissue-engineered regenerative material products that can replace and repair human tissues and organs, with the ambition of becoming a globally leading platform enterprise for the research, development, and manufacturing of artificial organ and tissue repair products.

Currently, there are hundreds of millions of patients with cardiovascular diseases and millions of hemodialysis patients worldwide. Although the continuous development of innovative treatment technologies, such as stents and balloons, has provided better care for many patients, a significant number of individuals with vascular diseases and those on hemodialysis still require treatments like vascular replacement or bypass surgery due to various reasons. At present, all commercially available artificial vascular products globally are made from polymer materials such as polytetrafluoroethylene (PTFE) and polyester. Due to the inherent limitations of these materials, a large number of patients cannot benefit from these artificial vascular products for their treatment.

LEADBIO stated, “The bio-based artificial blood vessels we have developed are poised to break through the barriers of traditional polymer-based artificial blood vessels, which cannot be made in small diameters and lack regenerative capacity. This advancement will usher in a new era of bio-based artificial blood vessels, providing a safe and revolutionary product for patients who cannot be treated with conventional methods.”

According to reports, LEADBIO’s first artificial vascular graft product will be used in arteriovenous graft (AVG) surgery for hemodialysis patients, with future potential for expansion into the treatment of other vascular diseases.

LEADBIO’s bio-based artificial blood vessel is currently the only medical product worldwide that combines polymer materials with decellularized matrix, with the polymer materials providing the blood vessel withExcellentmechanical properties, the decellularized matrix provides better biocompatibility for blood vessels and makes endothelialization of artificial blood vessels possible. This technology may also in the futureYingUsed in fields such as artificial esophagus, tissue repair, and plastic surgery.

(Artificial vascular graft products, photo provided by the company)

Cong Bo, Vice President of Boxing Capital, stated, “Biomaterials are a key area of focus for us, and we are highly optimistic about the development prospects of LEADBIO. The primary application of its artificial blood vessels is in dialysis, a field with a large patient base and a trend toward younger onset, offering broad market potential. Furthermore, the domestic market is currently monopolized by imported products, with a significant trend toward import substitution. LEADBIO’s artificial blood vessel technology is at the global forefront, demonstrating clear advantages over existing products, and its preliminary experimental results have been thoroughly validated. The company’s management team possesses extensive R&D and marketing experience, along with an international perspective, enabling it to keep pace with global R&D trends and domestic market demands. Leveraging the company’s R&D platform, it continues to develop products such as blood vessels and patches, thereby enriching its sales portfolio. We firmly believe that LEADBIO will consistently provide high-quality products to patients in China.”

Boxing Capital is a specialized investment firm focused on early-stage healthcare investments, founded by partners with extensive experience in medical investing. The firm currently manages funds totaling nearly RMB 1 billion, with key investments in over 30 innovative medical device and healthcare service projects that hold significant market potential. Many of these portfolio companies have grown into leaders in their respective sub-sectors, and the firm has successfully realized profitable exits from multiple investments. The limited partners behind Boxing Capital include top-tier domestic fund-of-funds, healthcare industry entrepreneurs, and seasoned investors. Leveraging in-depth industry research, clear investment logic, and comprehensive post-investment management capabilities, Boxing Capital has earned the long-term respect of entrepreneurs and secured continuous support from its investors, firmly establishing itself as a long-term partner to leading healthcare entrepreneurs and investors in China.

Taiyu Investment is an independent professional venture capital firm under Tigermed, a listed company, established in 2014. Taiyu Investment focuses on equity investments in the healthcare sector at early and growth stages. Its management team possesses extensive backgrounds in the pharmaceutical and health industries, broad industry resources, and rich experience in venture capital. To date, it has completed over RMB 1 billion in financing and investment activities, along with early-stage equity investments in more than 50 projects, primarily serving as a lead investor in Series A or Pre-A rounds. Its portfolio covers medical devices, biopharmaceuticals, health supplements, and CRO companies. By empowering its portfolio companies, Taiyu Investment creates value for the development of the healthcare industry in China and globally, contributing to public health.